# BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)

> **NCT03520920** · PHASE2 · COMPLETED · sponsor: **BeiGene** · enrollment: 41 (actual)

## Conditions studied

- Marginal Zone Lymphoma
- Follicular Lymphoma
- Diffuse Large B-Cell Lymphoma

## Interventions

- **DRUG:** Zanubrutinib
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT03520920
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-04
- **Primary completion:** 2020-08-28
- **Final completion:** 2020-08-28
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2024-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03520920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03520920, "BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03520920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*